Figure 7. In the phase II trial primary 2-dose series, neutralizing antibody titers (VNT50) against SARS-CoV-2 variants.
(A) Measurement of VNT50 against live SARS-CoV-2 virus variants in day 57 immune sera randomly selected from 48 vaccinees (n = 39 for young adults 18–65 years old; n = 9 for elderly adults ≥65 years old) who received 2 UB-612 vaccine doses in the phase II trial. Live WT SARS-CoV-2-TCDC#4 and USA WA1/2020, and 2 VoCs (B.1.1.7 and B.1.617.2 lineages) listed by WHO, were employed for CPE assays. The VNT50 values are marked on top of each column, with 95% CIs shown as horizontal bars. (B) The fold change (reduction) in VNT50 against each of the variants compared with WT strains Wuhan and USA WA1/2020 by the 2-sample t test. **P < 0.01; ****P < 0.0001. The 2.7- and 1.4-fold reductions also indicate 37% and 72% preservation of neutralization titers relative to the 2 WT strains isolated from 2 separate geographic locations where CPE assays were performed. Sinica, Academia Sinica, Taiwan; CDPH, California Department of Public Health.